Anuh Pharma Limited (ANUHPHR)
Outcome of Board Meeting
Press Release - Q2FY27
- Revenue 38.3bn +2% y-y; EBITDA 3.69bn (margin 9.7%, +260 bps y-y); PAT 2.26bn +42% y-y
- Bulk drug and Chemicals segment is the sole reportable segment
- EBITDA margin improved to 9.74% for H1FY27 from 7.13% in H1FY26
- Cash flow from operations positive at 2.67bn for H1FY27
- No subsidiaries or joint ventures as of Sep 30, 2026
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 ANUHPHR — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add ANUHPHR to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Anuh Pharma Limited
Important.
The summary above is generated automatically from Anuh Pharma Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.